Over the last four years, Biological E. Limited has embarked on a plan to expand the geographical footprint of its Pharma Division. While the focus of this effort will be on the development and commercialization of Non-Biological Complex Drugs (both complex APIs and formulations), the company also plans to develop routine injectable products in parallel to build a portfolio of both complex and routine injectable products.
Biological E. Limited has invested in building the infrastructure for R&D and manufacturing in Shameerpet, on the outskirts of Hyderabad. The R&D organization currently has a team of over 90 people working in Chemical R&D, Formulations R&D and Analytical R&D in addition to related support functions. The company’s new API facility and the formulation facility will be operational in Q2/Q3 2017. The formulation facility will be equipped to handle injectable products in vials and pre-filled syringes.
The emphasis of this new initiative will be primarily on the regulated markets, though the company will explore other markets as well as it continues to evolve.